Lower Costs, More Cures Act of 2019
Latest action · Dec 19, 2019 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedDec 9, 2019
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Lower Costs, More Cures Act of 2019
This bill establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs.
The bill generally
- limits payment amounts for drugs and biologics under Medicare medical services,
- reduces cost-sharing under the Medicare prescription drug benefit,
- modifies certain authorities and requirements under the Medicaid Drug Rebate Program,
- revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, and
- establishes several reporting requirements for drug manufacturers with respect to drug prices.
Cosponsors 147
Members who signed on, in the order they did. Signatures ran from Dec 9, 2019 to Aug 18, 2020; 111 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-GA | A. Drew Ferguson IV | Original | Dec 9, 2019 |
| R-IL | Adam Kinzinger | Original | Dec 9, 2019 |
| R-NE | Adrian Smith | Original | Dec 9, 2019 |
| R-MO | Ann Wagner | Original | Dec 9, 2019 |
| R-OH | Anthony Gonzalez | Original | Dec 9, 2019 |
| R-TX | Bill Flores | Original | Dec 9, 2019 |
| R-MI | Bill Huizenga | Original | Dec 9, 2019 |
| R-OH | Bill Johnson | Original | Dec 9, 2019 |
| R-MO | Billy Long | Original | Dec 9, 2019 |
| R-MO | Blaine Luetkemeyer | Original | Dec 9, 2019 |
| R-OH | Bob Gibbs | Original | Dec 9, 2019 |
| R-OH | Brad R. Wenstrup | Original | Dec 9, 2019 |
| R-KY | Brett Guthrie | Original | Dec 9, 2019 |
| R-TX | Brian Babin | Original | Dec 9, 2019 |
| R-AR | Bruce Westerman | Original | Dec 9, 2019 |
Committees 3
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Dec 9, 2019 |
| Health Subcommittee | Referred Dec 10, 2019 | |
| House | Ways and Means Committee | Referred Dec 9, 2019 |
| House | Judiciary Committee | Referred Dec 9, 2019 |
| Administrative State, Regulatory Reform, and Antitrust Subcommittee | Referred Dec 19, 2019 |
Actions 4
Everything that happened, newest first.
- Dec 19, 2019Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
- Dec 10, 2019Referred to the Subcommittee on Health.
- Dec 9, 2019Introduced in House
- Dec 9, 2019Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In the Congressional Record 7
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| House | Debate and remarks H7084, H7085 | Anna G. Eshoo D-CA, Donald M. Payne, Jr. D-NJ, Greg Walden R-OR, Michael C. Burgess R-TX | Dec 9, 2020 |
| House | Debate and remarks H2616, H2617, H2622, H2625, H2626, H2633 | Greg Walden R-OR, Larry Bucshon R-IN, Mike Kelly R-PA, Tom Reed R-NY, Virginia Foxx R-NC | Jun 29, 2020 |
| House | Debate and remarks H2433 | Michael C. Burgess R-TX | Jun 25, 2020 |
| House | Debate and remarks H964, H965 | Steve Scalise R-LA | Feb 7, 2020 |
| House | Debate and remarks H184 | Vicky Hartzler R-MO | Jan 13, 2020 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 196, December 9, 2019, page H9387.
Printed hearings 7
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
CRS reports 1
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 1
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
Related bills 34
Companion bills and other measures the record links to this one.
Titles 4
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes.
- Short Title(s) as Introduced
- Lower Costs, More Cures Act of 2019
- Short Title(s) as Introduced for portions of this bill
- Over-the-Counter Monograph User Fee Act of 2019
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Administrative remedies
- Advisory bodies
- Appropriations
- Biological and life sciences
- Business records
- Cancer
- Chemistry
- Child health
- Civil actions and liability
- Competition and antitrust
- Congressional oversight
- Consumer affairs
- Corporate finance and management
- Cosmetics and personal care
- Department of Health and Human Services
- Digestive and metabolic diseases
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Executive agency funding and structure
- Federal Trade Commission (FTC)
- Food and Drug Administration (FDA)
- Fraud offenses and financial crimes
- Genetics
- Government information and archives
- Government studies and investigations
- Health
- Health care costs and insurance
- Health information and medical records
- Health personnel
- Health programs administration and funding
- Health technology, devices, supplies
- Home and outpatient care
- Hospital care
- Immunology and vaccination
- Income tax deductions
- Income tax exclusion
- Inflation and prices
- Intellectual property
- Intergovernmental relations
- Judicial review and appeals
- Licensing and registrations
- Manufacturing
- Marketing and advertising
- Medicaid
- Medical education
- Medical research
- Medical tests and diagnostic methods
- Medicare
- Office of the U.S. Trade Representative
- Prescription drugs
- Product development and innovation
- Public participation and lobbying
- Research and development
- Retail and wholesale trades
- State and local government operations
- Trade agreements and negotiations
- User charges and fees
- Women's health
Text 1
Each version as it was printed, newest first.
- Dec 9, 2019Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
